CSL Limited (CSLLY)
OTCMKTS
· Delayed Price · Currency is USD
81.84
-0.89 (-1.08%)
Feb 21, 2025, 3:00 PM EST
CSL Limited Employees
CSL Limited had 32,698 employees as of June 30, 2024. The number of employees increased by 633 or 1.97% compared to the previous year.
Employees
32,698
Change (1Y)
633
Growth (1Y)
1.97%
Revenue / Employee
$465,778
Profits / Employee
$84,042
Market Cap
80.57B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 109 |
| SANUWAVE Health | 31 |
CSL Limited News
- 3 days ago - CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 9 days ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 11 days ago - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 12 days ago - Half Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 12 days ago - CSL Limited 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 12 days ago - CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 16 days ago - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - PRNewsWire